CMS Cuts Threaten Diabetes Device Margins —Here’s How AI Can Turn the Tide

The Centers for Medicare & Medicaid Services (CMS) recently proposed a sweeping 6.4% reduction to the Home Health Prospective Payment System (HH PPS) for Calendar Year 2026. While headlines have focused on the home-health industry’s reaction—closures, consolidation, and care deserts—there’s an underexamined but highly material ripple effect taking shape in the diabetes technology sector.

For manufacturers of Continuous Glucose Monitors (CGMs) and insulin pumps, this isn’t just a policy adjustment. It’s a structural disruption to a key commercial channel, with implications for margin stability, go-to-market architecture, and long-term reimbursement positioning.

The Overlooked Role of Home Health in Diabetes Tech

Home-health services play a pivotal, if often invisible, role in diabetes device adoption. Across Medicare and commercial populations alike, CGMs and insulin pumps are frequently delivered and initialized by home-health agencies. Nurses provide in-home setup, training, calibration, and adherence monitoring—particularly for elderly, disabled, or polymorbid patients.

This high-touch model helps optimize clinical outcomes and reduce readmissions, while supporting premium pricing by embedding the device within a broader care continuum.

Until now, that model has offered mutual reinforcement: better outcomes for patients, stronger reimbursement for providers, and higher margin realization for manufacturers. But with CMS now proposing over $1.1 billion in cuts—including a -4.059% permanent adjustment and a -5% “clawback” for previous overpayments—that alignment is under threat.